Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT05798117 | An Open-label, Study to Assess Safety, Efficacy and Cellular Kinetics of YTB323 in Severe, Refractory Systemic Lupus Erythematosus | PHASE1 | ACTIVE NOT_RECRUITING | 21 | — | — | Feb 28, 2023 | Sep 24, 2026 | Jun 2, 2026 | 10 | Australia, France +3 |
Long term safety follow up
| Arm | Type | Description |
|---|---|---|
| YTB323 | EXPERIMENTAL | Single infusion of YTB323 |
| Name | Type | Description |
|---|---|---|
| YTB323 | DRUG | Single infusion of YTB323 |
Inclusion Criteria: * Signed informed consent * Adequate renal, hepatic, cardiac, hematological and pulmonary function * Men and women with SLE, aged ≥18 years and ≤65 years at screening, fulfilling the 2019 European League Against Rheumatism EULAR/ACR classification criteria for SLE. * Patient mus...